Pasar al contenido principal

FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBRIMIENTO DE LIGANDOS QUE ACTUAN SINERGICAMENTE EN DOS PUNTOS DE CONTROL INMUNITARIOS EN EL MICROAMBIENTE TUMORAL

PID2021-124010OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands

  • Barbazán García, Jorge
  • Majellaro, María
  • Martínez Rodríguez, Antón Leandro
  • Brea Floriani, José Manuel
  • Sotelo Pérez, Eddy
  • Abal Posada, Miguel
G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases, but few therapies have been directed against GPCRs in the field of cancer, partly because of the lack of effective target identification strategies. Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor and stromal cells, identifying specific gene sets defining each cellular compartment. We selected the adenosine receptor 2B (A2BAR), specifically expressed in cancer cell lines compared with stromal cells, to explore the use of fluorescent ligands that can be used for target visualization. Fluorescent probes allowed semi-quantitative receptor mapping in living cells and validated the specific expression of A2BAR in CRC cell lines. As well, fluorescent ligands were effective at monitoring real-time A2BAR receptor labeling using live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor spheroids. Finally, we validated A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor cell proliferation. This proof-of-concept study suggests the use of fluorescent ligands for GPCR characterization through imaging, and as possible new tools used for target validation in drug screening methodologies
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Targeting the Adenosinergic Axis in Cancer Immunotherapy: Insights into A2A and A2B Receptors and Novel Clinical Combination Strategies

  • Rodríguez Pampín, Iván
  • González Pico, Lucía
  • Selas Lanseros, Asier
  • Andújar Arias, Antonio
  • Prieto Díaz, Rubén
  • Sotelo Pérez, Eddy
The extracellular accumulation of adenosine is a central mechanism of immune evasion within the tumor microenvironment. Elevated adenosine levels—driven by hypoxia, chronic inflammation, and upregulated ectonucleotidase activity, primarily through ectonucleoside triphophate diphosphoydrolase 1 and ecto-5′-nucleotidase—induce profound immunosuppression and promote tumor progression. In this setting, adenosine acts mainly through 2 G protein–coupled receptors, the adenosine A2A receptor (A2AAR) and the adenosine A2B receptor (A2BAR), which modulate diverse immune and stromal cell populations. A2AAR signaling suppresses the effector activity of cytotoxic T lymphocytes and natural killer cells, whereas A2BAR activation exerts broader effects by amplifying myeloid-derived immunosuppression, driving stromal remodeling, and fostering angiogenesis and metastatic dissemination. This review provides a comprehensive overview of the distinct and converging roles of A2AAR and A2BAR in immune, stromal, and tumor compartments. We critically analyze current strategies for developing selective and dual A2AAR/A2BAR antagonists, with a focus on structure-activity relationships, scaffold optimization, and pharmacokinetic profiling. In addition, we examine ongoing clinical trials and emerging combination therapies involving A2AAR and A2BAR antagonists in conjunction with immune checkpoint inhibitors, adoptive cell therapies, enzymatic axis blockade, radiotherapy, and classical chemotherapy. We also underscore the therapeutic potential of dual A2AAR/A2BAR antagonists as a multitarget approach to counteract overlapping immunosuppressive mechanisms. Overall, targeting the adenosine axis—particularly through dual receptor blockade—represents a promising strategy for reprograming the tumor microenvironment, reinvigorating antitumor immunity, and improving the efficacy of cancer immunotherapy.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB2 Agonists with Neuroprotective Effects

  • Prieto Díaz, Rubén
  • Gioé Gallo, Claudia
  • Ortigueira Noya, Sandra
  • García Mera, Xerardo
  • Azuaje Guerrero, Jhonny Alberto
  • Andújar Arias, Antonio
  • García Rey, Aitor
  • Graciano, Giovanni
  • Val García, Cristina
  • Martínez Rodríguez, Antón Leandro
  • Reza, David
  • Selas Lanseros, Asier
  • Francavilla, Fabio
  • Paleo Pillado, María Rita
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Sotelo Pérez, Eddy
This study presents the design, synthesis, and characterization of a novel series of structurally simple, selective, and functionally biased CB2 receptor (CB2R) agonists with potent anti-inflammatory and neuroprotective properties. These compounds were developed using a conformational restriction strategy to abolish CB1R binding, thereby enhancing CB2R selectivity. Pharmacological profiling identified ligands with distinct bias toward β-arrestin, MAPK, and G-protein signaling pathways. The series exhibits favorable drug-like properties, including high BBB permeability, low P-glycoprotein interaction, and microsomal stability. Representative compounds demonstrated neuroprotective activity in mouse primary neuronal assays and significantly reduced ROS and caspase levels in vitro, indicating mitigation of oxidative stress and apoptosis. In a neuron-like SH-SY5Y model expressing pathogenic mutations, they preserved neurite complexity in a CB2R-dependent manner. Collectively, these findings highlight the advantages of conformational restriction in transforming abused promiscuous, neurotoxic ligands into highly selective and efficacious agents for the treatment of neurodegenerative disorders, without CB1R-mediated psychoactive effects.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progress on the development of Class A GPCR-biased ligands

  • Morales, Paula
  • Scharf, Magdalena M.
  • Bermudez, Marcel
  • Egyed, Attila
  • Franco, Rafael
  • Hansen, Olivia K.
  • Jagerovic, Nadine
  • Jakubík, Jan
  • Keserű, György M.
  • Kiss, Dóra Judit
  • Kozielewicz, Pawel
  • Larsen, Olav
  • Majellaro, Maria
  • Mallo-Abreu, Ana
  • Navarro, Gemma
  • Prieto-Díaz, Rubén
  • Rosenkilde, Mette M.
  • Sotelo, Eddy
  • Stark, Holger
  • Werner, Tobias
  • Wingler, Laura M.
Class A G protein-coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numer- ous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signal- ling has opened up new pharmacological avenues holding promise for safer therapeu- tics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR-biased modulators with a focus on recent advances. Understanding the biological effects of this prefer- ential coupling is at different stages depending on the Class A GPCR family. There- fore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications., National Office of Research, Development and Innovation, Grant/Award Number: RRF- 2.3.1-21-2022-00015; Ministerio de Ciencia e Innovación, Grant/Award Numbers: FJC2021-047571-I, PID2020-118511RB-I00, PID2021-124010OB-100, PID2021-126600OB-I00, PID2021-127833OB-I00, PID2022- 139197OA-I00; Cancerfonden, Grant/Award Number: 20 0264; National Institutes of Health, Grant/Award Number: R01 DA0455698; German Research Foundation, Grant/Award Numbers: 470002134, GRK 2158; Swedish Society for Medical Research, Grant/Award Number: PG-22-0379-H-01; Hungarian Academy of Sciences, Grant/Award Number: NAP 3.0; Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government, Grant/Award Number: ED431B 2020/43; Centro Singular de Investigación de Galicia Accreditation 2019– 2022, Grant/Award Number: ED431G 2019/03; MCIN/ AEI/10.13039/501100011033/FEDER, UE, Grant/Award Number: FJC2021-047571-I; Karolinska Institutet, the Swedish Cancer Society, Grant/Award Number: 20 0264; Swedish Research Council, Grant/Award Number: 2022-01398; Czech Academy of Sciences, Grant/Award Number: 67985823; Grant Agency of Czech Republic, Grant/Award Number: 23-04670S; Juan de la Cierva Incorporación Programme, Grant/Award Number: IJC 2019-042182-I; The Pew Charitable Trusts; COST (European Cooperation in Science and Technology), Grant/Award Number: CA18133, Peer reviewed